286370-15-8 | 1-{2-Chloro-4-[(6,7-dimethoxyquinazolin-4-yl)oxy]phenyl}-3-propylurea

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$6.00	$4.00
5mg	98%	in stock	$13.00	$9.00
10mg	98%	in stock	$23.00	$17.00
50mg	98%	in stock	$69.00	$49.00
100mg	98%	in stock	$130.00	$91.00

Description

• Catalog Number: AB34476
• Chemical Name: 1-{2-Chloro-4-[(6,7-dimethoxyquinazolin-4-yl)oxy]phenyl}-3-propylurea
• CAS Number: 286370-15-8
• Molecular Formula: C20H21ClN4O4
• Molecular Weight: 416.8581
• MDL Number: MFCD14155620
• SMILES: CCCNC(=O)Nc1ccc(cc1Cl)Oc1ncnc2c1cc(OC)c(c2)OC

Computed Properties

• Complexity: 529
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 29
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 7
• XLogP3: 3.9

Literature

• A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

  The Biochemical journal 20130415

• Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model.

  The Journal of pathology 20120801

• Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.

  Nature biotechnology 20111101

• Suppression of hypoxia-induced HIF-1alpha accumulation by VEGFR inhibitors: Different profiles of AAL993 versus SU5416 and KRN633.

  Cancer letters 20101001

• Effects of KRN633, an inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase, on vascular development of placenta and fetus of mid-pregnancy in mice.

  Journal of pharmacological sciences 20100101

• A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.

  Proceedings of the National Academy of Sciences of the United States of America 20071218

• Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window.

  Molecular cancer therapeutics 20060101